Luigi Mangione, accused of murdering UnitedHealthcare CEO Brian Thompson, has withdrawn his plans to pursue a psychiatric defense in his upcoming New York murder trial. This decision was communicated by his attorney, Karen Agnifilo, in a letter to Manhattan Supreme Court Judge Gregory Carro. The withdrawal comes just one day after the legal team had notified the court of their intention to present this defense.
The change means that Mangione will not argue that he acted under an 'extreme emotional disturbance' during the shooting incident, which occurred on a Midtown Manhattan sidewalk in December 2024. His trial is scheduled to begin on September 8.
The psychiatric defense could have potentially reduced a murder conviction to first-degree manslaughter if the jury found that Mangione acted while suffering from severe emotional distress. However, this strategy would have required him to concede to the act of shooting while claiming that his mental state mitigated his responsibility.
Legal experts noted that the defense could have introduced broader discussions regarding the U.S. healthcare system into the trial. Prosecutors allege that Mangione expressed hostility toward UnitedHealthcare, noting that he wrote in journals about the company extracting 'human life force for money.' Additionally, ammunition recovered from the scene reportedly had inscriptions such as 'delay,' 'deny,' and 'depose,' which prosecutors argue reflect criticisms of health insurers.
Mangione's decision to abandon the psychiatric defense may also simplify his legal situation regarding a separate federal prosecution related to Thompson's death. He faces additional charges in Pennsylvania for allegedly possessing an unlicensed firearm. Unlike New York, federal courts do not recognize an extreme emotional disturbance defense, meaning any admission of guilt in the state trial could be used against him federally.